Barclays PLC Ligand Pharmaceuticals Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 43,456 shares of LGND stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,456

Previous 43,456 -0.0%

Holding current value

$5.17 Million

Previous $4.35 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$82.7 - $110.11 $599,326 - $797,967	7,247 Added 20.01%	43,456 $4.35 Million
Q2 2024 Aug 14, 2024	BUY	$68.53 - $87.91 $1.19 Million - $1.53 Million	17,421 Added 92.72%	36,209 $3.05 Million
Q1 2024 May 15, 2024	SELL	$68.64 - $89.2 $1.03 Million - $1.34 Million	-14,997 Reduced 44.39%	18,788 $1.37 Million
Q4 2023 Feb 15, 2024	BUY	$49.57 - $72.63 $793,913 - $1.16 Million	16,016 Added 90.13%	33,785 $2.41 Million
Q3 2023 Nov 07, 2023	BUY	$58.86 - $72.67 $198,122 - $244,607	3,366 Added 23.37%	17,769 $1.06 Million
Q2 2023 Aug 03, 2023	SELL	$69.53 - $79.33 $25,378 - $28,955	-365 Reduced 2.47%	14,403 $1.04 Million
Q1 2023 May 04, 2023	SELL	$65.67 - $77.08 $1.48 Million - $1.74 Million	-22,555 Reduced 60.43%	14,768 $1.09 Million
Q4 2022 Feb 13, 2023	BUY	$61.72 - $96.74 $589,426 - $923,867	9,550 Added 34.39%	37,323 $2.49 Million
Q3 2022 Nov 03, 2022	BUY	$0.01 - $107.56 $221 - $2.38 Million	22,147 Added 393.65%	27,773 $2.39 Million
Q2 2022 Aug 12, 2022	SELL	$74.52 - $117.06 $1.08 Million - $1.7 Million	-14,489 Reduced 72.03%	5,626 $502,000
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $3.49 Million - $5.57 Million	-36,739 Reduced 64.62%	20,115 $2.26 Million
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $1.55 Million - $2.02 Million	12,176 Added 27.25%	56,854 $8.78 Million
Q3 2021 Nov 09, 2021	BUY	$102.33 - $144.73 $1.36 Million - $1.92 Million	13,259 Added 42.2%	44,678 $6.22 Million
Q2 2021 Aug 13, 2021	SELL	$113.03 - $155.64 $998,054 - $1.37 Million	-8,830 Reduced 21.94%	31,419 $4.12 Million
Q1 2021 May 13, 2021	BUY	$99.52 - $215.83 $1.14 Million - $2.48 Million	11,488 Added 39.94%	40,249 $6.14 Million
Q4 2020 Feb 11, 2021	SELL	$80.55 - $106.05 $1.5 Million - $1.97 Million	-18,594 Reduced 39.27%	28,761 $2.86 Million
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $2.05 Million - $2.91 Million	-22,939 Reduced 32.63%	47,355 $4.51 Million
Q2 2020 Aug 12, 2020	SELL	$68.28 - $123.65 $682 - $1,236	-10 Reduced 0.01%	70,294 $7.86 Million
Q1 2020 May 13, 2020	SELL	$63.37 - $107.88 $1.33 Million - $2.27 Million	-21,016 Reduced 23.01%	70,304 $5.11 Million
Q4 2019 Feb 10, 2020	BUY	$96.94 - $113.59 $1.5 Million - $1.75 Million	15,446 Added 20.36%	91,320 $9.52 Million
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $1.47 Million - $2.05 Million	-17,047 Reduced 18.35%	75,874 $7.55 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $970,393 - $1.17 Million	9,037 Added 10.77%	92,921 $10.6 Million
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $1.73 Million - $2.33 Million	16,324 Added 24.16%	83,884 $10.5 Million
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $9.89 Million - $21 Million	-77,037 Reduced 53.28%	67,560 $9.17 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $1.04 Million - $1.35 Million	-4,914 Reduced 3.29%	144,597 $39.7 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $18.7 Million - $25.8 Million	124,227 Added 491.33%	149,511 $31 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $2.91 Million - $3.83 Million	20,990 Added 488.82%	25,284 $4.18 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $450,030 - $515,522	3,506 Added 444.92%	4,294 $588,000
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $95,277 - $108,696	788	788 $108,000

Others Institutions Holding LGND

# of Institutions

256

Shares Held

18M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account